Livzon Pharmaceutical Group Inc.

000513 · SZSE

Public Market Listing

000513SZSE

SZSE primary exchange listing

Live quotes, historical charts, and market capitalization for Livzon Pharmaceutical Group Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
IL-17A/FMonoclonal antibody
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 June 2026Filing acceptedLecankitugNMPA accepts the marketing application for lecankitug in ankylosing spondylitis (CXSS2600087)
China, NMPA · Livzon Pharmaceutical Group Inc. · Source ↗
December 2025Filing acceptedLecankitug Injection (LZM012)NMPA accepts the marketing authorisation application for lecankitug (LZM012) in plaque psoriasis
CN, NMPA · Livzon MABPharm Inc. · Source ↗
21 July 2025Topline resultLZM012Phase 3 head-to-head vs secukinumab met its primary endpoint (PASI 100 at week 12)
Livzon MABPharm Inc. · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.7B———report ↗